Methods of treating myeloproliferative disorders

Administering Compound I, a JAK2 inhibitor, in conjunction with thiamine supplementation, addresses the challenge of thiamine deficiency in myeloproliferative disorders, effectively managing the disorders and preventing associated complications.

JP2024161416AInactive Publication Date: 2024-11-19IMPACT BIOMEDICINES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024125670
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-20
Filing Date
2024-08-01
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for myeloproliferative disorders, such as myelofibrosis, often lead to thiamine deficiency, which can result in adverse events like Wernicke's encephalopathy, and there is a need for effective therapeutic agents that can manage these disorders while mitigating such deficiencies.

Method used

Administering Compound I, a JAK2 inhibitor, to patients with myeloproliferative disorders, and monitoring and adjusting thiamine levels through supplementation to prevent deficiency, particularly in conjunction with thiamine or its equivalents.

Benefits of technology

The method effectively reduces the severity of myeloproliferative disorders and prevents thiamine deficiency, improving patient outcomes and reducing the risk of complications like Wernicke's encephalopathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161416000001
    Figure 2024161416000001
  • Figure 2024161416000002
    Figure 2024161416000002
  • Figure 2024161416000003
    Figure 2024161416000003
Patent Text Reader

Abstract

To provide pharmaceutical compositions for use in methods of treating, stabilizing or alleviating the severity or progression of one or more myeloproliferative disorders.SOLUTION: The present invention provides pharmaceutical compositions for use in methods of treating myeloproliferative disorders and alleviating thiamine deficiency, comprising compound I, or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The methods include (i) administering, to a patient in need thereof, compound I, or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient; and (ii) simultaneously administering, to the patient at risk for developing thiamine deficiency, thiamine or a thiamine equivalent concurrently with the compound I, or the pharmaceutically acceptable salt or hydrate thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 736,369, filed September 25, 2018, and U.S. Provisional Application No. 62 / 783,076, filed December 20, 2018, which are hereby incorporated by reference in their entireties.

[0002] The present invention provides methods for treating, stabilizing, or reducing the severity or progression of a myeloproliferative disorder. [Background technology]

[0003] The search for new therapeutic agents has been greatly aided in recent years by an improved understanding of the structure of disease-associated enzymes and other biomolecules. One important class of enzymes that has been the subject of extensive study is the protein kinases.

[0004] Protein kinases constitute a large family of structurally related enzymes responsible for controlling various signaling processes in cells. Protein kinases are thought to have evolved from a common ancestral gene because of the conservation of their structure and catalytic function. Nearly all kinases have a similar 250-300 amino acid catalytic domain. Kinases can be classified into several families according to the substrates they phosphorylate (e.g., protein tyrosine, protein serine / threonine, lipids, etc.).

[0005] In general, protein kinases mediate intracellular signal transduction by effecting phosphoryl transfer from a nucleoside triphosphate to a protein acceptor involved in a signal transduction pathway. These phosphorylation events act as molecular on / off switches that can regulate or control target protein biological functions. These phosphorylation events are ultimately triggered in response to a variety of extracellular and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, and H2O2), cytokines (e.g., interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α)), and growth factors (e.g., granulocyte macrophage colony stimulating factor (GM-CSF) and fibroblast growth factor (FGF)). Extracellular stimuli can affect one or more cellular responses associated with cell proliferation, migration, differentiation, hormone secretion, transcription factor activation, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.

[0006] Many diseases are associated with the abnormal cell reaction caused by the above-mentioned protein kinase mediated events.These diseases include, but are not limited to, autoimmune disease, inflammatory disease, bone disease, metabolic disease, neurological and neurodegenerative disease, cancer, cardiovascular disease, allergy and asthma, Alzheimer's disease, and hormone-related disease.Therefore, there is still a need to find protein kinase inhibitors that are useful as therapeutic agents. Summary of the Invention

[0007] The present disclosure provides a method for treating, stabilizing or reducing the severity or progression of one or more myeloproliferative disorders.In certain embodiments, the provided method comprises reducing one or more adverse events associated with the treatment of myeloproliferative disorders.In some of such embodiments, the one or more adverse events are thiamine deficiency.

[0008] In some embodiments, the disclosure provides a method of treating, stabilizing, or reducing the severity or progression of one or more myeloproliferative disorders, the method comprising administering to a patient a compound of formula I: [ka] or a pharma- ceutically acceptable composition comprising a pharma- ceutically acceptable salt or hydrate thereof. The compound of formula I is also referred to herein as "compound I." In some embodiments, compound I is in the dihydrochloride salt form. Compound I or a pharma- ceutically acceptable salt thereof can also exist in the hydrate form. In some such embodiments, compound I is in the dihydrochloride monohydrate form. Thus, in some embodiments, the methods provided include administering compound II to a patient in need thereof: [ka]

[0009] In some embodiments, the present disclosure provides a method for treating a myeloproliferative disorder, the method comprising: (i) administering to a patient in need of treatment Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); (ii) monitoring the patient's thiamine levels; Adjusting the patient's thiamine level if it is below normal; Includes.

[0010] In some embodiments, the patient's thiamine level is adjusted if the thiamine level is about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more lower than the reference level. In some embodiments, the reference level is the patient's thiamine level at baseline, prior to administration of Compound I. In some embodiments, the reference level is a whole blood thiamine level of about 74 nM / L to about 222 nM / L.

[0011] In some embodiments, the patient is at risk of developing Wernicke's encephalopathy.

[0012] In some embodiments, the patient's thiamine levels are assessed by analyzing one or more biomarkers for thiamine deficiency. In some embodiments, the biomarker for thiamine deficiency is serum thiamine levels.

[0013] In some embodiments, the patient's thiamine levels are adjusted by administering thiamine or a thiamine equivalent to the patient.

[0014] In some embodiments, the present disclosure provides a method of treating a patient comprising: (i) administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); (ii) analyzing the patient's thiamine level; and (iii) if the patient's thiamine level is lower than about 74 nM / L to about 222 nM / L of whole blood but higher than about 30 nM / L of whole blood, administering thiamine or a thiamine equivalent to the patient.

[0015] In some embodiments, the patient is administered 100 mg of thiamine per day. In some embodiments, the patient is administered sufficient thiamine equivalents to deliver about 100 mg of thiamine per day. In some such embodiments, the thiamine or thiamine equivalent is administered orally.

[0016] In some embodiments, the present disclosure provides a method of treating a patient comprising: (i) administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); (ii) analyzing the patient's thiamine level; and (iii) administering thiamine or a thiamine equivalent to the patient if the patient's thiamine level is below about 30 nM / L of whole blood.

[0017] In some embodiments, the thiamine or thiamine equivalent is administered intravenously. In some embodiments, the thiamine is administered to the patient in an amount of about 250 mg. In some embodiments, the thiamine is administered to the patient in an amount of about 250 mg per day (QD). In some embodiments, the patient is administered sufficient thiamine equivalent to deliver about 250 mg of thiamine per day.

[0018] In some embodiments, thiamine is administered to the patient in an amount of about 500 mg. In some embodiments, thiamine is administered to the patient in an amount of about 500 mg per day (QD). In some embodiments, the patient is administered sufficient thiamine equivalents to deliver about 500 mg thiamine QD. In some embodiments, thiamine is administered to the patient in an amount of about 500 mg three times a day (TID). In some embodiments, the patient is administered sufficient thiamine equivalents to deliver about 500 mg thiamine TID.

[0019] In some embodiments, thiamine is administered to a patient in an amount of about 500 mg TID for 2 or 3 days, followed by thiamine administration in an amount of about 250 mg to about 500 mg QD for 3-5 days, followed by thiamine administration in an amount of about 100 mg QD for 90 days.

[0020] In some embodiments, the methods provided further comprise increasing magnesium levels in the patient.

[0021] In some embodiments, the patient suffers from a myeloproliferative disorder. In some such embodiments, the myeloproliferative disorder is myelofibrosis. In some embodiments, the myelofibrosis is primary myelofibrosis. In some embodiments, the primary myelofibrosis is Dynamic International Prognostic Scoring System (DIPSS) intermediate or high risk primary myelofibrosis. In some embodiments, the myelofibrosis is secondary myelofibrosis. In some embodiments, the myelofibrosis is post-essential thrombocythemia myelofibrosis. In some embodiments, the myelofibrosis is post-polycythemia vera myelofibrosis. In some embodiments, the myeloproliferative disorder is polycythemia vera. In some embodiments, the myeloproliferative disorder is essential thrombocythemia. In some embodiments, the myeloproliferative disorder is acute myeloid leukemia (AML).

[0022] In some embodiments, the present disclosure provides a method of treating a patient comprising: (i) administering Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); and (ii) Conduct a cognitive assessment.

[0023] In some embodiments, the cognitive assessment is performed during the second 28-day cycle. In some embodiments, the cognitive assessment is performed during the third 28-day cycle. In some embodiments, the cognitive assessment is performed during the third of at least every three 28-day cycles. In some embodiments, the cognitive assessment comprises a Mini-Mental State Examination. In some embodiments, the method further comprises analyzing the patient's thiamine levels.

[0024] definition The term "about" as used herein, when referring to a measurable value such as a parameter, amount, length of time, etc., is meant to encompass a variation of + / -10% or less from the specified value, preferably + / -5% or less, more preferably + / -1% or less, even more preferably + / -0.1% or less, to the extent that such variation is reasonable in the invention of the present disclosure. For example, when the term "about" is used in conjunction with a specific number of days, it includes the specific number of days plus or minus one day, for example, "about 6 days" includes any number of days from 5 to 7. Of course, the value indicated by the modifier "about" is itself specific and preferably disclosed.

[0025] The term "biomarker" is used herein to denote an entity, event, or characteristic whose presence, level, degree, type, and / or form correlates with a particular biological event or condition of interest and is therefore considered to be a "marker" for that event or condition. To name just a few examples, in some embodiments, a biomarker may be or include a marker for a particular disease state, or a marker for the likelihood of developing, occurring, or recurring a particular disease, disorder, or condition. In some embodiments, a biomarker may be or include a marker for a particular disease or treatment outcome, or the likelihood thereof. Thus, in some embodiments, a biomarker is a predictive marker, in some embodiments, a prognostic marker, and in some embodiments, a diagnostic marker, for the relevant biological event or condition of interest. A biomarker may be or include any chemical class of entity, and may be or include a combination of entities. For example, in some embodiments, a biomarker may be or include a nucleic acid, a polypeptide, a lipid, a carbohydrate, a small molecule, an inorganic agent (e.g., a metal or ion), or a combination thereof. In some embodiments, the biomarker is a cell surface marker. In some embodiments, the biomarker is an intracellular marker. In some embodiments, the biomarker is detected outside the cell (e.g., the marker is secreted or otherwise produced or present outside the cell, e.g., in a bodily fluid such as blood, urine, tears, saliva, cerebrospinal fluid, etc.). In some embodiments, the biomarker may be or include a genetic signature or an epigenetic signature. In some embodiments, the biomarker may be or include a gene expression signature.

[0026] As used herein, the term "combination therapy" refers to a situation in which a subject is administered two or more treatment regimens (e.g., two or more therapeutic agents, including one or more compounds as described herein) at the same time. The two or more regimens may be administered simultaneously or sequentially (e.g., all doses of a first regimen are administered, followed by any doses of a second regimen). In other embodiments, the compounds are administered in overlapping dosing regimens. "Administration" of combination therapy may involve administering one or more compounds to a subject that is also administered other compound(s). For clarity, combination therapy does not require that the individual compounds be administered together in a single composition (or even at the same time or by the same route of administration), although in some embodiments, two or more compounds may be administered together in a combined composition, or even in a combined compound (e.g., as part of a single chemical complex or conjugated entity).

[0027] The term "thiamine equivalent" refers to an agent that delivers or is capable of delivering a biologically equivalent amount of thiamine. Such thiamine equivalents include prodrugs of thiamine, as well as thiamine derivatives, such as thiamine monophosphate, thiamine pyrophosphate (also known as thiamine diphosphate), and thiamine triphosphate. In some embodiments, the thiamine equivalent is a dietary form of thiamine, such as that found in vegetables or other food sources.

[0028] The term "treat" or "treating" as used herein refers to partially or completely alleviating, inhibiting, delaying the onset of, preventing, ameliorating, and / or alleviating a disorder or condition, or one or more symptoms of a disorder or condition. As used herein, the terms "treatment", "treat", and "treating" refer to partially or completely alleviating, inhibiting, delaying the onset of, preventing, ameliorating, and / or alleviating a disorder or condition, or one or more symptoms of a disorder or condition, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In some embodiments, the term "treating" includes preventing or halting the progression of a disease or disorder. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a suspected individual prior to the onset of symptoms (e.g., in light of a symptom history and / or in light of genetic or other factors). Treatment may be continued after symptoms have resolved, e.g., to prevent or delay their recurrence. Thus, in some embodiments, the term "treating" includes preventing the recurrence or recurrence of a disease or disorder.

[0029] The term "unit dosage form" as used herein refers to a physically discrete unit of the formulation of the present invention appropriate for the subject to be treated. However, it will be understood that the total daily usage of the composition of the present invention will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dose level for any particular subject or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific active agent used; the specific composition used; the age, weight, general health, sex, and diet of the subject; the administration timing and excretion rate of the specific active agent used; the duration of treatment; drugs and / or additional therapies used in combination or concurrently with the specific compound(s) used, and similar factors well known in the pharmaceutical arts. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Detailed Description of Specific Embodiments Myelofibrosis Myeloproliferative neoplasms (MPNs)-associated myelofibrosis (MF) is a severe and life-threatening disease that may present as de novo or primary myelofibrosis (PMF) or develop from a previous polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF) (Swerdlow SH, Campo E, Harris NL, Jafie ES, Pileri SA, Stein H, et al. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press 2008). The disease is characterized by clonal myeloproliferative proliferation, ineffective erythropoiesis, bone marrow stromal changes, extrahepatic hematopoiesis, and ectopic cytokine expression (Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011 Sep;25(5):229-37). Patients typically present with splenomegaly, constitutional symptoms, moderate to severe anemia, thrombocytopenia, and leukocytosis.

[0031] Primary myelofibrosis is a member of the group of Philadelphia chromosome (Ph1)-negative MPNs, which also includes PV and ET (Tefferi A. The recent advances in classic BCR-ABL-negative myeloproliferative disorders. Clin. Adv. Hematol. Oncol. 2007a;5:113-5). Nearly all patients with PV and about half of patients with ET and PMF have a JAK2 mutation, typically JAK2V617F. Other mutations in patients with PMF include CALR and MPL. Approximately 20% of patients with PMF have no detectable mutations in JAK2, CALR, or MPL and are referred to as triple negative (Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97; Werning G, Mercher T, Okabe R, Levine L, Lee BH, Gilliland GL. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-81). Mutations in JAK2, CALR, and MPL lead to activation of the JAK / STAT signaling pathway, resulting in cell proliferation and inhibiting cell death.The result is clonal proliferation. (Ilhe JN, Gilliland DG. JAK2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 2007;17:8-14) Thus, JAK2 inhibitors that can downregulate the JAK / STAT pathway are expected to be useful in reducing cell proliferation.

[0032] Polycythemia vera (PV) and essential thrombocythemia (ET) are characterized by elevated levels of red blood cells (RBCs) and platelets. However, approximately 10% of affected patients develop myelofibrosis, which is morphologically distinct from PMF. These conditions are called post-PV MF and post-ET MF (Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. Hematology Am. Soc. Hematol. Educ. Program. 2005;201-8), and the clinical name is MPN-associated myelofibrosis. Patients with MPN-associated myelofibrosis have a similar survival prognosis to PMF and a cumulative risk of transformation to acute myeloid leukemia (AML) of approximately 10%.

[0033] There are several prognostic scoring systems that predict survival in patients with PMF. The International Prognostic Scoring System (IPSS) is used to predict survival at the time of diagnosis, and the Dynamic International Prognostic Scoring System (DIPSS) is used at any time point during the disease course (Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;Mar 26;113(13):2895-901;Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 Mar 4;115(9):1703-8). Variables included in the IPSS are age >65 years, constitutional symptoms, hemoglobin level <10 g / dL, and white blood cell (WBC) count. More recent prognostic scoring systems include the Dynamic International Prognositic Scoring System Plus (DIPSS Plus) and scoring systems that incorporate data from mutational analysis.A strong association exists between overall survival and DIPSS risk classification in patients with MF, with median survival of 15.4, 6.5, 2.9, and 1.3 years for patients with low-risk, intermediate-1, intermediate-2, or high-risk disease, respectively (Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2016 Dec;91(12):1262-1271).

[0034] Approximately 70% of individuals with MF are in the intermediate2 or high-risk category (Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 2011 Feb 1;29(4):392-7), representing the largest unmet medical need. Symptomatic enlargement of the spleen and liver, the need for RBC transfusions, cachexia, and other MF-associated symptoms significantly impair the quality of life of these patients (Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep;21(9):1964-70).

[0035] Compound I The synthesis of Compound I is disclosed in Example 90 of U.S. Patent No. 7,528,143, issued May 5, 2009, which is hereby incorporated by reference in its entirety. Compound I, also known as fedratinib, is a potent and selective inhibitor of JAK2 kinase activity, which inhibits JAK2 signaling, mutant JAK2 or mutant MPL-driven cell proliferation in cell assays, and induces apoptosis in cells expressing constitutively active JAK2. Compound I also inhibits erythroid colony formation of hematopoietic progenitor cells isolated from patients with myeloproliferative neoplasms (MPN).

[0036] Myelofibrosis (MF) is a clonal disease caused by mutations in CD34+ hematopoietic stem cells that drive aberrant proliferation and myeloid differentiation (Mead AJ, 2017). In addition to JAK2V617F, multiple other mutations in JAK2 and other genes are found in MF patients and have been associated with prognosis, AML progression, and response to the JAK inhibitor ruxolitinib (Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679, Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Mar 23;Spiegel JY, McNamara C, Kennedy JA, Panzarella T, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1 / 2 inhibitor therapy. Blood. 2017 Sep 8;1(20):1729-1738;Newberry KJ, Patel K, Masarova L, Luthra R, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 Aug 31;130(9):1125-1131;Patel KP, Newberry KJ, Luthra R, Jabbour E, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Blood. 2015 Aug 6;126(6):790-7;Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97;Werning G, Mercher T, Okabe R, Levine L, Lee BH, Gilliland GL. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-81;Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood. 2006 Oct 15;108(8):2770-9;Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med.2007 Feb 1;356(5):459-68;Pardanani A, Tefferi A, Jamieson C, Gabrail NY, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 7;5:e335)。.

[0037] Phosphorylated STAT3 (pSTAT3) is a downstream effector of activated JAK2. Tracking pSTAT3 levels in circulating cells has proven to be a useful pharmacodynamic (PD) biomarker of fedratinib JAK2 engagement in MF patients (Pardanani A, Tefferi A, Jamieson C, Gabrail NY, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 7;5:e335). Preclinical data indicates that fedratinib can also inhibit pSTAT5, and it has been reported that basal levels of pSTAT5 in AML cells predict response to fedratinib in AML xenograft models (Chen WC, Yuan JS, Xing Y, Mitchell A, Mbong N, et al. An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Res. 2016 Mar 1;76(5):1214-24).Abnormal cytokine expression and myelofibrosis are unmistakable features of MF (Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679;Mondet J, Hussein K, Mossuz P. Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest. Mediators Inflamm. 2015;2015:670580). High levels of proinflammatory and fibrogenic cytokines have been reported to contribute to bone marrow (BM) stromal changes, ineffective erythropoiesis / extramedullary hematopoiesis, and systemic symptoms in MF (Mondet J, Hussein K, Mossuz P. Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest. Mediators Inflamm. 2015;2015:670580;Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011 Sep;25(5):229-37).Fedratinib was found to modulate circulating cytokines in MF patients who had not previously been treated with a JAK inhibitor (Pardanani A, Tefferi A, Jamieson C, Gabrail NY, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 7;5:e335). Cytokine modulation correlated with sustained virologic response (SVR) and improvement of systemic symptoms in such patients (Pardanani A, Tefferi A, Jamieson C, Gabrail NY, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 7;5:e335).

[0038] Recent studies are beginning to elucidate an immunomodulatory role for JAK2V617F, as well as for JAK inhibitors such as ruxolitinib. For example, JAK2V617F has been found to contribute to immune evasion of MPN myeloid cells by upregulating programmed cell death ligand 1 (PD-L1) (Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, et. al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 2018 Feb 21;10(429)), and ruxolitinib has been reported to modulate PD-L1 expression in these cells (Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, et. al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 2018 Feb 21;10(429)).However, preclinical and clinical data indicate that ruxolitinib is also a potent immunosuppressant, capable of suppressing graft-versus-host disease (GVHD), reducing the frequency of T and NK cells, and preventing their activation in patients with MF (Betts BC, Bastian D, Iamsawat S, Nguyen H, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci US A. 2018 Feb 13;115(7):1582-1587. Epub 2018;Schonberg K, Rudolph J, Vonnahme M, Parampalli et al. Cancer JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Res. 2015 Jun 1;75(11):2187-99;Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, et al. JAK1 / 2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br. J. Haematol. 2015 Jun;169(6):824-33).Preclinical data suggest that fedratinib can modulate PD-L1 expression in lymphoma tumor cells (Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin. Cancer Res. 2014 May 15;20(10):2674-83). However, fedratinib is not a potent suppressor of GVHD, nor does it inhibit human T cell development in xenograft mouse models (Betts BC, Veerapathran A, Pidala J, Yang H, et al. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Sci Transl Med. 2017 Jan 11;9(372)). The selective activity of fedratinib against JAK2 raises the possibility that fedratinib may exert immunomodulatory functions in patients with MF without compromising T-cell or NK-cell function.

[0039] In some embodiments, the disclosure provides methods of preventing and / or alleviating thiamine deficiency in a patient administered Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II). In some embodiments, the disclosure provides methods of treating a patient, the methods comprising administering Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) and monitoring the patient's thiamine levels.

[0040] In some embodiments, the disclosure provides a method for treating a myeloproliferative disorder, the method comprising: (i) administering to a patient in need of treatment a JAK1 and / or JAK2 inhibitor; and (ii) Monitoring the patient's thiamine levels.

[0041] In some such embodiments, the method further includes adjusting the patient's thiamine level if the thiamine level is below a reference value (e.g., a baseline level). In some embodiments, the JAK1 and / or JAK2 inhibitor is Compound I or a pharma- ceutically acceptable salt thereof (e.g., Compound II).

[0042] Thus, in some embodiments, the present disclosure provides a method for treating a myeloproliferative disorder, the method comprising: (i) administering to a patient in need of treatment Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); (ii) monitoring the patient's thiamine levels; Adjust the patient's thiamine level if it is below normal Includes.

[0043] In some embodiments, the patient's thiamine levels are assessed by analyzing one or more biomarkers for thiamine deficiency. In some embodiments, the biomarker for thiamine deficiency is serum thiamine levels.

[0044] In some embodiments, the level of the biomarker is compared to a reference value. In some embodiments, the reference value is a baseline level of the biomarker (e.g., the biomarker level before administration of Compound I or Compound II). In some embodiments, the reference value is a biomarker level that is considered to be within the range typically observed in a healthy population (e.g., a population not affected by the target disease or disorder). In some embodiments, the reference value is a biomarker level that is considered to be within the range typically observed in a population diagnosed with the target disease or disorder.

[0045] In some embodiments, the biomarker level following administration of Compound I or Compound II is lower than the reference value (eg, lower than the baseline level of the biomarker).

[0046] In some embodiments, the patient's thiamine level is adjusted if the thiamine level is about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more lower than the reference level. In some embodiments, the reference level is the patient's baseline thiamine level prior to administration of Compound I or Compound II. In some embodiments, the reference level is a thiamine level of about 74 nM / L to about 222 nM / L of whole blood.

[0047] In some embodiments, the patient is at risk of developing Wernicke's encephalopathy.

[0048] In some embodiments, the patient's thiamine levels are adjusted by administering thiamine or a thiamine equivalent to the patient.

[0049] In some embodiments, the present disclosure provides a method of treating a patient comprising: (i) administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); (ii) analyzing the patient's thiamine level; and (iii) administering thiamine or a thiamine equivalent to the patient if the patient's thiamine level is below about 30 nM / L of whole blood.

[0050] In some embodiments, the present disclosure provides a method of alleviating thiamine deficiency, the method comprising administering Compound I, or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II), to a patient at risk of developing thiamine deficiency, where the patient is also simultaneously exposed to thiamine or a thiamine equivalent.

[0051] In some such embodiments, the patient is administered about 100 mg of thiamine per day. In some embodiments, the patient is administered sufficient thiamine equivalents to deliver about 100 mg of thiamine per day. In some embodiments, the thiamine or thiamine equivalent is administered orally.

[0052] In some embodiments, the patient is administered thiamine equivalents that deliver about 100 mg of thiamine per day.

[0053] In some embodiments, the disclosure provides a combination therapy comprising: (i) Compound I, or a pharma- ceutically acceptable salt or hydrate thereof (eg, Compound II); and (ii) thiamine or a thiamine equivalent.

[0054] In some embodiments, the disclosure provides a method of treating myelofibrosis, the method comprising administering to a patient in need of treatment a combination therapy comprising Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) and thiamine or a thiamine equivalent. In some such embodiments, the thiamine is administered in an amount of about 100 mg per day (QD). In some embodiments, the patient is administered sufficient thiamine equivalent to deliver about 100 mg of thiamine per day. In some embodiments, the thiamine or thiamine equivalent is administered orally.

[0055] In some such embodiments, thiamine is administered in an amount of about 500 mg TID thiamine. In some such embodiments, the patient is administered about 250 or about 500 mg QD thiamine. In some embodiments, the patient is administered sufficient thiamine equivalents to deliver about 250 mg or about 500 mg QD thiamine per day. In some embodiments, about 250 mg or about 500 mg thiamine is administered orally. In some embodiments, the thiamine equivalents are administered orally.

[0056] In some embodiments, the thiamine equivalent is thiamine pyrophosphate.

[0057] In some embodiments, the provided methods further include increasing magnesium levels in the patient. In some embodiments, the magnesium levels in the patient are increased by administering a magnesium supplement.

[0058] In some embodiments, the patient is suffering from a myeloproliferative disorder.

[0059] In some embodiments, the myeloproliferative disorder is myelofibrosis. In some embodiments, the myelofibrosis is primary myelofibrosis. In some embodiments, the myelofibrosis is secondary myelofibrosis. In some embodiments, the myelofibrosis is post-essential thrombocythemia myelofibrosis. In some embodiments, the myelofibrosis is post-polycythemia vera myelofibrosis.

[0060] In some embodiments, the myeloproliferative disorder is polycythemia vera. In some embodiments, the myeloproliferative disorder is essential thrombocythemia. In some embodiments, the myeloproliferative disorder is acute myeloid leukemia.

[0061] In some embodiments, Compound I is administered in the dihydrochloride monohydrate form (eg, Compound II).

[0062] In some embodiments, compound I or its pharma- ceutically acceptable salt or hydrate (e.g., compound II) is administered to a patient in a unit dosage form. In some embodiments, the unit dosage form of compound I or compound II is based on the free base weight of the compound. For example, a dose of 100 mg of compound I in free base form is equivalent to about 117.30 mg when compound I is in its dihydrochloride monohydrate form (i.e., compound II). In some embodiments, the unit dosage form of compound I or compound II is about 50 mg, about 100 mg, about 150 mg, or about 200 mg based on the free base weight of the compound. In some embodiments, the unit dosage form of compound I or compound II is 100 mg based on the free base weight of the compound.

[0063] In some embodiments, Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) is administered in an oral dosage form. In some such embodiments, the oral dosage form is a capsule. In some embodiments, the oral dosage form is a tablet.

[0064] In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once a day (QD). In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered in a total daily dose of about 200 mg, about 300 mg, or about 400 mg. In some embodiments, compound I or compound II is administered to the patient in a total daily dose of about 400 mg. In some embodiments, compound I or compound II is administered to the patient in a total daily dose of about 300 mg. In some embodiments, compound I or compound II is administered to the patient in a total daily dose of about 200 mg. In some embodiments, the total daily dose of compound I or compound II is adjusted due to adverse events. In some embodiments, the total daily dose of compound I or compound II is reduced. In some embodiments, the total daily dose of compound I or compound II is reduced from about 400 mg to about 300 mg. In some embodiments, the total daily dose of Compound I or Compound II is reduced to about 200 mg.

[0065] In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once daily for one 28-day cycle. In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once daily for two 28-day cycles. In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once daily for three, four, five, or more 28-day cycles. In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once daily for six, seven, eight, nine, ten, eleven, twelve, or more 28-day cycles. In some embodiments, compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., compound II) is administered once a day until symptoms of the disease are no longer measurable. In some embodiments, compound I or compound II is administered for the patient's lifetime. In some embodiments, compound I or compound II is administered once a day for one or more 28-day cycles, followed by a drug holiday. "Drug holiday" as used herein refers to a length of time during which compound I or compound II is not administered to the patient. In some embodiments, the drug holiday is a day, a week, or a 28-day cycle. In some embodiments, compound I or compound II is administered once a day for one or more 28-day cycles, followed by a drug holiday, and then once a day administration of compound I or compound II is resumed at the same dose level as before the drug holiday. In some embodiments, Compound I or Compound II is administered once daily for one or more 28-day cycles, followed by a drug holiday, and then resumption of once daily administration of Compound I or Compound II at a dose level 100 mg lower than the dose level of Compound I or Compound II prior to the drug holiday. In some embodiments, the total daily dose of Compound I or Compound II is titrated in 100 mg increments after the previous dose reduction.

[0066] In some embodiments, provided methods include administering Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) once daily for two or more 28-day cycles. In some such embodiments, the patient's thiamine levels are assessed at the beginning of the second 28-day cycle.

[0067] In some embodiments, the methods provided include administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) once a day for two or more 28-day cycles, with the patient's thiamine level being assessed at the beginning of each 28-day cycle. In some embodiments, the methods provided include administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) once a day for two or more 28-day cycles, with the patient's thiamine level being assessed at the end of each 28-day cycle. In some embodiments, the methods provided include administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) once a day for two or more 28-day cycles, with the patient's thiamine level being assessed at the beginning of a second 28-day cycle and at the beginning of a third 28-day cycle. In some such embodiments, the patient's thiamine level is assessed at the beginning of every third 28-day cycle thereafter. For example, if a patient is treated for twelve 28-day cycles, thiamine levels are assessed on day 1 (± 3 days) of each of the second, third, sixth, ninth, and twelfth cycles. In some embodiments, the methods provided include administering to a patient Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II) once daily for six or more 28-day cycles, and the patient's thiamine levels are assessed at the beginning of each of the first, second, third, fourth, fifth, and sixth cycles.

[0068] In some embodiments, methods provided include administering thiamine or a thiamine equivalent to a patient when the patient's thiamine level is below normal (e.g., 74-222 nM / L of whole blood) but is greater than or equal to 30 nM / L of whole blood. In some such embodiments, the thiamine or thiamine equivalent is administered orally. In some embodiments, the thiamine is administered to the patient at a dose of about 100 mg per day. In some embodiments, the patient is administered sufficient thiamine equivalent to deliver about 100 mg of thiamine per day.

[0069] In some embodiments, the methods provided include administering thiamine or a thiamine equivalent if the patient's thiamine level is below 30 nM / L of whole blood. In some such embodiments, the thiamine is administered to the patient according to the following schedule: (i) about 500 mg three times a day (TID) for 2 or 3 days; (ii) about 250 mg to about 500 mg (QD) daily for 3 to 5 days, and (iii) about 100 mg QD daily for at least 90 days.

[0070] In some embodiments, patients with thiamine levels below 30 nM / L of whole blood are administered sufficient thiamine equivalents to deliver a constant amount of thiamine according to the following schedule: (i) about 500 mg three times a day (TID) for 2 or 3 days; (ii) about 250 mg to about 500 mg (QD) daily for 3 to 5 days, and (iii) about 100 mg QD daily for at least 90 days.

[0071] In some embodiments, the thiamine or thiamine equivalent is administered intravenously.

[0072] In some embodiments, the methods provided further comprise monitoring the magnesium level of the patient. In some such embodiments, the methods provided comprise increasing the magnesium level of the patient.

[0073] In some embodiments, the patient has a myeloproliferative disorder or condition. In some embodiments, the myeloproliferative disorder or condition is selected from primary myelofibrosis, secondary myelofibrosis, polycythemia vera, essential thrombocythemia, post-polycythemia vera, and post-essential thrombocythemia. In some embodiments, the myeloproliferative disorder is acute myeloid leukemia (AML). In some embodiments, the primary myelofibrosis is Dynamic International Prognostic Scoring System (DIPSS) intermediate or high risk primary myelofibrosis. In some embodiments, the method comprises administering to a patient in need of treatment a composition according to the invention.

[0074] In some embodiments, the present disclosure provides a method of treating a patient comprising: (i) administering Compound I or a pharma- ceutically acceptable salt or hydrate thereof (e.g., Compound II); and (ii) Conduct a cognitive assessment.

[0075] In some embodiments, the cognitive assessment is performed during the second 28-day cycle. In some embodiments, the cognitive assessment is performed during the third 28-day cycle. In some embodiments, the cognitive assessment is performed during the third of at least every three 28-day cycles. In some embodiments, the cognitive assessment comprises a Mini-Mental State Examination. In some embodiments, the method further comprises analyzing the patient's thiamine levels. EXAMPLES

[0076] Protocol Summary: A multicenter, single-arm, open-label efficacy and safety study of fedratinib in subjects with intermediate or poor risk primary myelofibrosis (PMF), post-polycythemia vera (post-PV MF), or post-essential thrombocythemia MF (post-ET MF) previously treated with ruxolitinib.

[0077] Objectives: The primary objective of this study is to evaluate the percentage of subjects with at least 35% spleen volume reduction with fedratinib. Secondary objectives are: To evaluate the safety of fedratinib -Evaluate splenic size reduction by palpation To assess myelofibrosis (MF)-related symptoms as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) To assess the duration of splenic reaction by MRI / CT and by palpation -To assess the duration of symptomatic response To evaluate the effectiveness of risk mitigation strategies for gastrointestinal (GI) events To evaluate the effectiveness of risk reduction strategies for Wernicke's encephalopathy (WE).

[0078] Exploratory studies included the following: To evaluate overall survival (OS) To assess the effect of the study treatment on selected treatment-related symptoms (diarrhoea, nausea, vomiting, dizziness, headache) from the subject's perspective using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). - Search for prognostic markers (e.g., gene mutations) at baseline and in relation to efficacy parameters - To explore biomarkers related to the mechanism of action of fedratinib (e.g., circulating cytokines)

[0079] Study Population: The study plans to enroll approximately 110 subjects with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF).

[0080] All subjects who discontinue protocol-defined treatment for any reason will be followed for survival, subsequent treatment, and progression of myelofibrosis to acute myeloid leukemia (AML) every 3 months until death, up to 12 months after end of treatment (EOT), loss to follow-up, withdrawal of consent for further data collection, or end of the study, whichever occurs first.

[0081] Study Design. The study is planned to have three phases: 28-day screening period Duration of fedratinib treatment, including 30-day follow-up after the last dosing visit 12-month survival follow-up period

[0082] Length of the study. The expected duration of the study is approximately 4 years, including approximately 18 months of full enrollment and 24 months of treatment and follow-up.

[0083] The end of the study will be defined as the date when the last subject completed survival follow-up at their last visit or the date when the last data point required for primary, secondary, and / or exploratory analyses was received from the last subject, whichever is later, as pre-specified in the study protocol.

[0084] Screening Period. All enrolled subjects will undergo a screening procedure during the screening period, which must be completed within 28 days prior to the start of study treatment. This serves to determine subject eligibility based on all inclusion and exclusion criteria defined in the study protocol. The screening period may be extended up to 35 days (7 additional days) for subjects who receive ruxolitinib during the screening period or for subjects who may reverse laboratory abnormalities detected during screening (or other criteria that would exclude a subject from enrollment).

[0085] Treatment Duration. Once eligibility is confirmed, subjects will be enrolled and treated with continuous use of fedratinib at a dose of 400 mg orally once daily. Fedratinib will be administered as the dihydrochloride monohydrate form (i.e., Compound II). A cycle is defined for dosing purposes as a 4-week (28-day) period. Unless otherwise noted, visits will have a ±3-day window, with the exception of MRI / CT scan procedures, which have a ±7-day window. Site visits will be conducted on days 1 and 15 during the first three cycles, and on day 1 during subsequent cycles. On day 8 of cycle 1, the site will contact the subject by telephone to assess the occurrence and counsel on management of nausea, vomiting, and diarrhea. Subjects may continue treatment with fedratinib until unacceptable toxicity, lack of therapeutic effect, or consent is withdrawn. All subjects will be monitored for adverse events throughout the study. All subjects who discontinue protocol-defined treatment for any reason will be followed for 30 days after their last dose of fedratinib.

[0086] Fedratinib is self-administered orally once daily on an outpatient basis, preferably with the evening meal, at the same time each day. If a dose is missed, the next dose should be taken the next day at the same time as the previous dose was taken before the missed dose.

[0087] During the first three cycles, site visits will occur on days 1 and 15, and during subsequent cycles on day 1. On day 8 of cycle 1, the site will contact subjects by telephone to assess the occurrence of and discuss management of nausea, vomiting, and diarrhea.

[0088] Subjects may continue treatment with fedratinib until unacceptable toxicity, lack of therapeutic efficacy, disease progression, or consent is withdrawn.

[0089] All subjects will be monitored for adverse events throughout the study.

[0090] All subjects who discontinue protocol-defined treatment for any reason will be followed for 30 days after their last dose of fedratinib.

[0091] The most common adverse events associated with fedratinib are hematological and gastrointestinal adverse events. Hematological adverse events associated with JAK inhibitors are dose-dependent and mechanism-based, and they are managed through dose reductions, dose interruptions, and transfusions.

[0092] The fedratinib dose in this study is 400 mg / day. If a subject experiences drug toxicity as specified in the dose modification schedule (Table 1), dosing should be interrupted and dose modifications may be necessary.

[0093] If the subject is intolerant to fedratinib treatment after two dose level reductions from the starting dose, the subject must discontinue participation in study treatment. If toxicity does not resolve in the time period specified in the dose modification schedule (Table 1), the subject must discontinue participation in study treatment. Dose re-escalation is possible in certain cases as defined in the dose modification schedule (Table 1). The daily dose of fedratinib cannot exceed 400 mg / day.

[0094] Subjects may continue to be treated with fedratinib until unacceptable toxicity, lack of therapeutic efficacy, or the subject is noncompliant with treatment or withdraws consent.

[0095] Dose modification schedule

[0096] A flexible dose modification regimen can be used to minimize drug toxicity for individual subjects, with possible daily doses of 200 mg, 300 mg, or 400 mg.

[0097] The most common adverse events associated with fedratinib are hematological and gastrointestinal adverse events. Hematological adverse events associated with JAK inhibitors are dose-dependent and mechanism-based, and they are managed through dose reductions, dose interruptions, and transfusions.

[0098] Dosing must be discontinued if a subject experiences drug toxicity as specified in Table 1 below. In some cases (i.e., in the absence of abnormal liver function tests (LFTs)), doses may be titrated in decrements of 100 mg / day during the study, down to a minimum dose of 200 mg / day, based on the investigator's discretion. Fedratinib doses will be adjusted for subjects with severely impaired renal function and for subjects receiving coadministration of strong or moderate CYP3A4 inhibitors.

[0099] If the subject is intolerant to fedratinib after two dose levels below the starting dose, the subject must discontinue participation in study treatment. If toxicity does not resolve in the time period specified in Table 1, the subject must discontinue participation in study treatment. Dose re-escalation is possible in certain cases. The daily dose of fedratinib cannot exceed 400 mg / day (based on free base weight). [Table 1] [Table 2]

[0100] Dose Adjustments for Coadministration of Strong or Moderate CYP3A4 Inhibitors

[0101] Coadministration of fedratinib with strong or moderate CYP3A4 inhibitors may increase fedratinib exposure, which may increase the risk of exposure-related AEs and should be considered carefully.

[0102] For subjects receiving concomitant strong CYP3A4 inhibitors, a reduction in the starting dose of fedratinib from 400 mg to 200 mg is recommended. If introduction of a strong CYP3A4 inhibitor is required during fedratinib treatment, consider decreasing the dose level by two steps (e.g., from 300 mg to 100 mg). Strong CYP3A4 inhibitors include, but are not limited to, boceprevir, cobicistat, conivaptan, danoprevir-ritonavir, elvitegravir-ritonavir, grapefruit juice, indinavir-ritonavir, itraconazole, ketoconazole, lopinavir-ritonavir, paritaprevir-ritonavir (ombitasvir and / or dasabuvir), posaconazole, ritonavir, saquinavir-ritonavir, telaprevir, tipranavir-ritonavir, troleandomycin, and voriconazole.

[0103] For subjects receiving a moderate CYP3A4 inhibitor concomitantly, it is recommended to reduce the starting dose of fedratinib from 400 mg to 300 mg. If it is required to introduce a moderate CYP3A4 inhibitor during fedratinib treatment, consider lowering the dose level by one level (e.g., from 300 mg to 200 mg). Moderate CYP3A4 inhibitors include, but are not limited to, aprepitant, cimetidine, ciprofloxacin, clotrimazole, crizotinib, cyclosporine, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, tofisopam, and verapamil.

[0104] If reduction of the fedratinib dose below 100 mg per day is necessary based on any fedratinib-related AEs due to potential increases in fedratinib plasma concentrations, consider a lower average daily dose, for example, by administering 100 mg fedratinib every other day, which is equivalent to an average daily dose of 50 mg.

[0105] If AEs persist after reduction in the fedratinib dose, consider interrupting either fedratinib or the strong CYP3A4 inhibitor based on the overall benefit / risk for the patient.

[0106] If coadministration with a CYP3A4 inhibitor is discontinued, the fedratinib dose should be re-escalated accordingly.

[0107] Dose Adjustments for Renal Impairment. No dose adjustments are recommended in subjects with mild and moderate renal impairment. In subjects who develop severe renal impairment during clinical trials, the fedratinib dose should be adjusted by one dose level downward (e.g., from 400 mg to 300 mg once daily [QD]). Subjects with a planned dose of 200 mg QD may be reduced to 100 mg.

[0108] Management of Latent Wernicke's Encephalopathy (WE)

[0109] A potential WE is a medical emergency. Screening for and management of potential WE during treatment with fedratinib will follow the following steps:

[0110] Clinical and cognitive assessment. Intermediate medical history: Includes reviewing the subject's history for confusion, memory impairment, visual disturbances (e.g., diplopia), as well as signs and symptoms of malnutrition, malabsorption, and alcohol use. Physical Examination: Includes assessment of abnormal eye movements, cerebellar abnormalities, and weight (weight loss compared to previous exams or patient history) during screening and at Day 1 of every treatment cycle, at the end of treatment (EOT), and at the Day 30 follow-up visits Mini-Mental State Examination (MMSE): To objectively assess signs / symptoms of encephalopathy, performed during screening, on day 1 of cycles 2 and 3, then every 3 cycles, at EOT, and more frequently if clinically indicated

[0111] Management of potential WE. If there are signs or symptoms that may indicate a WE: Withhold fedratinib until WE is ruled out Obtain a sample for thiamine levels · Start an experimental thiamine supplementation Report the event to the sponsor as an AESI Get neurological advice · Perform a brain MRI If WE is confirmed, permanently discontinue fedratinib

[0112] Thiamine monitoring and correction. Thiamine levels (whole blood) will be monitored and all subjects with thiamine levels below the normal range will be given thiamine supplementation. Thiamine levels should be assessed at screening and should be corrected and retested before initiating fedratinib treatment. During treatment with fedratinib, thiamine levels will be assessed at the start of cycles 2, 3, and every 3 cycles thereafter or as clinically indicated: - If the subject is receiving thiamine supplementation, thiamine levels must be assessed in the fasting state with respect to thiamine supplementation, and thiamine is administered after blood sampling. - If the thiamine level result is below normal, the study site will contact the subject as soon as possible to begin thiamine supplementation. - Thiamine levels below normal but ≥ 30 nM / L and no signs or symptoms of WE: Oral supplementation of thiamine 100 mg should be initiated If results are obtained from a local laboratory, report the event to the sponsor as an Adverse Event of Special Interest (AESI). -Thiamine levels <30nM / L, with or without signs or symptoms of WE: · Treat immediately with thiamine (preferably intravenously (IV)) in therapeutic dosages (e.g., 500 mg infusion over 30 minutes three times a day for 2 to 3 days) or an equivalent amount intramuscularly (IM) according to local standard of care; Report the event to the sponsor as an Adverse Event of Special Interest (AESI) followed by 250 mg to 500 mg IV thiamine infusion once daily for 3 to 5 days, or equivalent IM dose according to local standard of care; Then, continue with oral thiamine at a dose of 100 mg per day for at least 90 days. Fedratinib should be held until thiamine levels are restored to the normal range. -Thiamine supplementation must be administered as a thiamine-only formulation. -If thiamine levels are low, ensure that magnesium levels are normal and, if low, correct them * Adverse events of special interest (AESIs) are one of scientific and medical interest specific to the understanding of an investigational drug and may require close monitoring and prompt reporting by the investigator to the sponsor.

[0113] The following are considered adverse events of special interest (AESI): · Cases of Wernicke's encephalopathy (WE) or suspected WE with thiamine levels below the normal range. Thiamine levels below the normal range, with or without signs or symptoms of WE New malignant tumors after initiation of study treatment Progression of myelofibrosis to acute myeloid leukemia (AML) Heart failure or hypertrophy Grade 3 and 4 hyperlipasemia or grade 3 and 4 hyperamylasemia or pancreatitis events according to CTCAE criteria v5.0 Grade 3 or 4 elevations in alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin, or hepatotoxic events

[0114] Management of Nausea and Vomiting. Management of nausea and vomiting during treatment with fedratinib will follow the following steps: Before treatment begins, subjects will be provided with management instructions (including when to contact the study site). It is recommended that fedratinib be taken with food at dinner time to reduce nausea and vomiting episodes. During the first 8 weeks of treatment, it is strongly recommended to use prophylactic anti-nausea / vomiting medications (e.g., ondansetron) according to local practice. If dimenhydrinate or other muscarinic receptor antagonists are used for nausea and vomiting, these agents should be administered at night to minimize the potential for drowsiness and other neurological AEs. Withhold / reduce fedratinib dose according to Table 1 Hospitalization may be required for grade 3 or greater nausea or vomiting or persistent events For medications administered for prophylactic use against nausea and vomiting, consider weaning subjects from these medications if no clinically significant nausea or vomiting occurs during the first 8 weeks of fedratinib treatment.

[0115] Management of diarrhea. Management of diarrhea during treatment with fedratinib will follow the following steps: Subjects should have loperamide available at home and be provided with instructions for diarrhea management (including when to contact the study site) prior to initiating treatment. Loperamide should not be administered as a prophylaxis unless the subject is experiencing diarrhea. At the onset of diarrhea, treat with loperamide as per local practice. Initiate loperamide at an initial dose of 4 mg, then consider 2 mg for each diarrheal bowel movement, but not to exceed 16 mg / 24 hours. Dietary modifications, including adequate hydration, avoidance of lactose-containing foods and alcohol, and small meals of rice, bananas, and bread Withhold / reduce fedratinib dose according to Table 1 For persistent diarrhea of ​​grade 3 or greater, hospitalization may be required Management of nausea, vomiting, and diarrhea will be assessed during subject visits on Day 1 of every subsequent 28-day cycle, and via mandatory telephone contacts on Day 15 of the first three cycles, and Day 8 of the first cycle.

[0116] Summary of key efficacy measures. Unless otherwise specified, analyses of spleen volume response will be performed in the efficacy-evaluable population, myelofibrosis symptom response analyses will be performed in the MFSAF population, and analyses of spleen size response will be performed in the safety population.

[0117] Splenic volume response rate (RR) by MRI / CT. Spleen volume reduction response rate will be defined as the proportion of subjects with ≥ 35% spleen volume reduction at the end of cycle 6 compared to baseline. Response rates and 95% confidence intervals will be provided. Descriptive summary statistics of spleen volume measurements and percentage change from baseline will also be provided. Subjects without MRI / CT spleen volume data at the end of cycle 6, including subjects who met criteria for splenomegaly progression before the end of cycle 6, will be considered non-responders.

[0118] A sensitivity analysis will be performed on the response rate of subjects who achieved ≥25% spleen volume reduction at the end of cycle 6 compared to baseline.

[0119] Splenic Response Rate by Palpation (RRP). Splenic Response Rate by Palpation is the proportion of subjects with a splenic response according to IWG-MRT2013 at the end of cycle 6 compared to baseline. This will be calculated for subjects with splenomegaly (5cm or more below LCM) at baseline. Subjects without splenic size assessment at the end of cycle 6 will be considered non-responders, including subjects who met criteria for splenomegaly progression before the end of cycle 6. Response rates and 95% confidence intervals will be provided.

[0120] Symptomatic response rate (SRR). Symptomatic response rate (SRR) is defined as the proportion of subjects who achieved a ≥ 50% reduction from baseline in total symptom score (TSS) by the end of cycle 6 as measured by MFSAF version 4.0. SRR and 95% confidence intervals will be provided. TSS will be defined as the sum of the scores for each of the seven symptoms (Gwaltney C, Paty J, Kwitkowski VE, Mesa RA, Dueck AC, Papadopoulos EJ, et al. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res. 2017 Aug;59:26-31). To allow indirect comparison with previous MF studies, a modified TSS (Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2013 Apr 1;31(10):1285-92) will also be calculated for the six symptoms examined (night sweats, pruritus, abdominal discomfort, early satiety, left subcostal pain, and bone or muscle pain), and an analysis of SRRs will also be performed.

[0121] At each time point, TSS (based on seven symptoms) and modified TSS will be calculated. Descriptive summary statistics (size, mean, standard deviation, median, range) will be provided for baseline scores, post-baseline scores, and changes from baseline in TSS, modified TSS, and symptom scores.

[0122] Subjects without baseline TSS>0 will be considered non-evaluable (due to lack of symptom reduction) for SRR analysis. Subjects without TSS at the end of cycle 6 or who progress before the end of cycle 6 will be considered non-responders.

[0123] Duration of splenic volume response by MRI / CT (DR). Duration of splenic volume response by MRI / CT (DR) is defined as the time from the first reported splenic response (i.e., ≥35% reduction in splenic volume) to the first reported reduction in splenic volume <35%. In the absence of an event (i.e., continued <35% reduction in splenic volume from prior to analysis), the DR will be censored at the date of the last valid assessment prior to the analysis date.

[0124] Spleen volume response duration by MRI / CT scan will be analyzed using the Kaplan-Meier method. KM estimates at the 25th, 50th, and 75th percentiles as well as 95% confidence intervals for the median will be provided. KM curves will be plotted.

[0125] Duration of Palpable Splenic Reaction (DRP). Duration of palpable splenic reaction (DRP) is defined as the time from the first reported palpable splenic reaction according to IWG-MRT2013 to the first reported decrease in reaction according to IWG-MRT2013. Duration of palpable splenic reaction according to IWG-MRT2013 criteria will be calculated for subjects with splenomegaly (5 cm or more below LCM) at baseline and for subjects with palpable splenic reaction. In the absence of an event (i.e., no decrease in palpable splenic reaction) prior to the analysis, the DRP will be censored at the date of the last valid assessment made prior to the analysis date.

[0126] Duration of symptomatic response (DSR). Duration of symptomatic response is defined as the first reported TSS response (i.e., ≥ 50% reduction in TSS) as measured by MFSAF version 4.0 to the first reported < 50% reduction in TSS. In the absence of a < 50% reduction in TSS prior to the analysis, the DSR will be censored at the date of the last valid assessment prior to the analysis date. The DRS will be analyzed using the KM method. KM estimates for the 25th, 50th, and 75th percentiles and 95% confidence intervals for the median will be provided. The KM curve will be plotted.

[0127] [Table 3] [Table 4] [Table 5] AE = adverse event; C1D1 = day 1 of cycle 1; CTC = Common Terminology Criteria for Adverse Events; ICF = informed consent form; MFSAF = Myelofibrosis Symptom Assessment Form; MRI = magnetic resonance imaging; NCI = National Cancer Institute; PRO-CTCAE = Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events; SVR = spleen volume reduction.

[0128] Survival Follow-Up Period. All subjects who discontinue protocol-defined treatment for any reason will be followed for survival, subsequent treatments, new malignancies, and progression of myelofibrosis to acute myeloid leukemia (AML) every 3 months until death, up to 12 months after end of treatment (EOT), loss to follow-up, withdrawal of consent for further data collection, or end of the study, whichever occurs first.

Claims

1. A method for treating a myeloproliferative disorder, comprising: (i) administering to a patient in need of treatment Compound I or a pharma- ceutically acceptable salt or hydrate thereof; and (ii) monitoring the patient's thiamine level, wherein if the thiamine level is lower than a reference level, adjusting the patient's thiamine level; The method comprising:

2. 10. The method of claim 1, wherein the patient's thiamine level is assessed by analyzing one or more biomarkers for thiamine deficiency.

3. 3. The method of claim 2, wherein the biomarker for thiamine deficiency is serum thiamine levels.

4. The method of claim 2 or claim 3, wherein the level of the biomarker after administration of compound I is lower than the reference value.

5. 5. The method of claim 1, wherein the patient's thiamine level is adjusted by administering thiamine or a thiamine equivalent to the patient.

6. 1. A method for treating myelofibrosis, comprising administering to a patient in need of treatment a combination therapy comprising Compound I, or a pharma- ceutical acceptable salt or hydrate thereof, and thiamine or a thiamine equivalent.

7. 1. A method for alleviating thiamine deficiency, comprising administering Compound I, or a pharma- ceutically acceptable salt or hydrate thereof, to a patient at risk of developing thiamine deficiency, wherein the patient is simultaneously exposed to thiamine or a thiamine equivalent.

8. 8. The method of any one of claims 1 to 7, wherein the thiamine equivalent is thiamine pyrophosphate.

9. 1. A method of treating a patient, comprising: (i) administering to said patient Compound I, or a pharma- ceutically acceptable salt or hydrate thereof; (ii) analyzing the patient's thiamine level; and (iii) if the patient's thiamine level is less than about 30 nM / L, administering thiamine or a thiamine equivalent to the patient. The method comprising:

10. 10. The method of claim 9, wherein thiamine is administered to the patient in an amount of about 100 mg per day.

11. 11. The method of claim 10, wherein the thiamine is administered orally.

12. 10. The method of claim 9, wherein thiamine is administered to the patient in an amount of about 250 mg to about 500 mg.

13. 13. The method of claim 12, wherein thiamine is administered to the patient in an amount of about 250 mg.

14. 13. The method of claim 12, wherein thiamine is administered to the patient in an amount of about 500 mg.

15. 15. The method of any one of claims 12 to 14, wherein thiamine is administered intravenously.

16. Thiamine is taken on the following schedule: Approximately 500 mg TID for 2 or 3 days, About 250 mg to about 500 mg QD for 3 to 5 days, and Approximately 100 mg QD for 90 days The method of claim 9 , wherein the compound is administered according to

17. 10. The method of claim 9, wherein the patient is administered sufficient thiamine equivalents to deliver about 100 mg of thiamine per day.

18. 20. The method of claim 17, wherein the thiamine equivalent is administered orally.

19. 10. The method of claim 9, wherein the patient is administered sufficient thiamine equivalents to deliver about 250 mg to about 500 mg of thiamine.

20. 20. The method of claim 19, wherein the thiamine equivalents are sufficient to deliver about 250 mg of thiamine.

21. 20. The method of claim 19, wherein the thiamine equivalents are sufficient to deliver about 500 mg of thiamine.

22. 22. The method of any one of claims 19 to 21, wherein the thiamine equivalent is administered intravenously.

23. The thiamine equivalents are administered according to the following schedule: Approximately 500 mg TID for 2 or 3 days, About 250 mg to about 500 mg QD for 3 to 5 days, and Approximately 100 mg QD for 90 days 20. The method of claim 17, wherein the amount of thiamine is sufficient to deliver an amount of thiamine in accordance with

24. 24. The method of any one of claims 1 to 23, further comprising increasing magnesium levels in the patient.

25. 25. The method of any one of claims 1 to 24, wherein the patient is suffering from a myeloproliferative disorder.

26. 26. The method of claim 25, wherein the myeloproliferative disorder is myelofibrosis.

27. 27. The method of claim 26, wherein the myelofibrosis is primary myelofibrosis.

28. 28. The method of claim 27, wherein the primary myelofibrosis is selected from intermediate-risk primary myelofibrosis and high-risk primary myelofibrosis.

29. 27. The method of claim 26, wherein the myelofibrosis is secondary myelofibrosis.

30. 27. The method of claim 26, wherein the myelofibrosis is post-essential thrombocythemia myelofibrosis.

31. 27. The method of claim 26, wherein the myelofibrosis is post-polycythemia vera myelofibrosis.

32. 26. The method of claim 25, wherein the myeloproliferative disorder is acute myeloid leukemia (AML).

33. 26. The method of claim 25, wherein the myeloproliferative disorder is polycythemia vera.

34. 26. The method of claim 25, wherein the myeloproliferative disorder is essential thrombocythemia.

35. 1. A method of treating a patient, comprising: (i) administering Compound I or a pharma- ceutically acceptable salt or hydrate thereof; and (ii) Conducting a cognitive function assessment The method comprising:

36. 36. The method of claim 35, wherein the evaluation is performed during a second 28-day cycle of Compound I administration.

37. 36. The method of claim 35, wherein the evaluation is performed during a third 28-day cycle of Compound I administration.

38. 36. The method of claim 35, wherein the evaluation is performed during the third of at least every three 28-day cycles of Compound I administration.

39. 36. The method of claim 35, wherein the assessment comprises a Mini-Mental State Examination.

40. 36. The method of claim 35, further comprising analyzing the patient's thiamine levels.

Citation Information

Patent Citations

  • Compositions and methods for treating myelofibrosis

    JP2013541595A